FMS logo

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an) (FMS)

$21.69

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on FMS

Market cap

$12.12B

EPS

3.94

P/E ratio

10.8

Price to sales

0.52

Dividend yield

4.018%

Beta

0.792192

Price on FMS

Previous close

$21.86

Today's open

$21.78

Day's range

$21.69 - $21.94

52 week range

$20.02 - $26.42

Profile about FMS

CEO

Shervin J. Korangy

Employees

106291

Headquarters

Bad Homburg,

Exchange

New York Stock Exchange

Shares outstanding

558577770

Issue type

American Depository Receipt

FMS industries and sectors

Healthcare

Healthcare Providers & Services

News on FMS

Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses

Washington Attorney General Nick Brown on Tuesday filed a lawsuit accusing the state's two largest for-profit dialysis providers of imposing illegal noncompete agreements on medical directors, blocking competition and reducing care options for kidney failure patients.

news source

Benzinga • Nov 12, 2026

news preview

What Fresenius Medical Care AG & Co. KGaA (FMS) Said on Its Q3 Earnings Call

Fresenius Medical Care AG & Co. KGaA NYSE: FMS reported broadly stable third-quarter revenue and a decline in operating income as reimbursement pressures and inflation weighed on results, while the company continued to advance its U.S. rollout of high-volume hemodiafiltration technology and execute its share repurchase program.

news source

MarketBeat • Nov 4, 2026

news preview

Fresenius raises 2026 outlook for second time after strong Q3

Healthcare ​group Fresenius lifted its full-year expectations on Wednesday after ‌reporting higher-than-anticipated third-quarter results, as strong performance at the Kabi and Helios divisions supported earnings.

news source

Reuters • Nov 4, 2026

news preview

Fresenius Medical cuts top end of 2026 profit outlook

German dialysis specialist Fresenius Medical Care ​cut the upper end of its 2026 operating income ‌outlook on Tuesday after US treatment volumes declined for a third consecutive quarter, as regulatory and inflation headwinds weighed on quarterly earnings.

news source

Reuters • Nov 3, 2026

news preview

Fresenius Medical Care AG (FMS) Q3 2026 Earnings Call Transcript

Fresenius Medical Care AG (FMS) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 3, 2026

news preview

Fresenius Medical Care reports third quarter 2026 performance partially offsetting headwinds and narrowing full year outlook

Stable organic revenue1 development driven by growth in Care Delivery and Care Enablement, offset by the expected decline in profit-neutral Value-Based Care Operating income2 decreased by 6%, due to regulatory and inflation headwinds Reported operating income decreased by 19% and reported net income3 decreased by 42%, mainly due to one-time costs related to the China strategy refinement Earnings per share2 (EPS) remained stable supported by the share buyback program 348 U.S. clinics representing 16% of our U.S. dialysis machines converted to the 5008X CAREsystem™ with 1.3 million treatments4 FY 2026 outlook – revenue outlook broadly flat, operating income outlook narrowed to between flat and a negative mid-single digit percent growth rate BAD HOMBURG, Germany, Nov. 3, 2026 /PRNewswire/ -- "Three weeks into my role as CEO, I am energized by the opportunities ahead. As a global leader in kidney care, Fresenius Medical Care combines exceptional capabilities with unparalleled reach.

news source

PRNewsWire • Nov 3, 2026

news preview

FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI

Fresenius Medical Care launches multiFiltratePRO kidney therapy system in the United States, expanding critical care options and growth opportunities.

news source

Zacks Investment Research • Oct 23, 2026

news preview

Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™

Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S. FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous kidney replacement therapy options for U.S. patients requiring treatment for acute kidney injury Integrated technology helps hospital intensive care teams deliver complex treatment simply and efficiently BAD HOMBURG, Germany, Oct. 21, 2026 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for people with kidney disease, today announced the U.S. launch of the multiFiltratePRO System for critically ill patients with acute kidney injury (AKI). multiFiltratePRO's integrated technology eliminates the need for separate citrate and calcium pumps, and automatically adjusts as treatment conditions change, making complex treatment easier for hospital intensive care teams to manage.

news source

PRNewsWire • Oct 21, 2026

news preview

Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026

BAD HOMBURG, Germany, Oct. 19, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, presents new research and evidence-driven innovations aimed at improving patient outcomes during the American Society of Nephrology's (ASN) Kidney Week 2026, taking place October 21-25 in Denver, Colorado.

news source

PRNewsWire • Oct 19, 2026

news preview

Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

FMS' transformation is lifting profitability, while HDF, value-based care and cost savings offset volume and reimbursement pressures.

news source

Zacks Investment Research • Oct 7, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an)

Open an M1 investment account to buy and sell Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an) commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in FMS on M1